ER/PR pharmDx™ Interpretation Manual - Dako
ER/PR pharmDx™ Interpretation Manual - Dako
ER/PR pharmDx™ Interpretation Manual - Dako
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
References<br />
1. Elledge RM, Fuqua sAw. Estrogen and progesterone receptors.<br />
In: Harris, et al, editors. Diseases of the breast. Philadelphia: lippincott,<br />
williams & wilkins; 2000. p. 471-3.<br />
2. Fitzgibbons Pl, Page Dl, weaver D, thor AD, Allred DC, Clark GM,<br />
et al. Prognostic factors in breast cancer. College of American<br />
Pathologists Consensus statement 1999. Arch Pathol lab Med.<br />
2000;124:966-78.<br />
3. bardou VJ, Arpino G, Elledge RM, osborne CK, Clark GM. Progesterone<br />
receptor status significantly improves outcome prediction over estrogen<br />
receptor status alone for adjuvant endocrine therapy in two large breast<br />
cancer databases. J Clin oncol. 2003;21:1973-9.<br />
4. Rhodes A, Jasani b, balaton AJ, Miller KD. Immunohistochemical<br />
demonstration of oestrogen and progesterone receptors: correlation<br />
of standards achieved on in house tumours with that achieved on<br />
external quality assessment material in over 150 laboratories from<br />
26 countries. J Clin Pathol. 2000;53:292-301.<br />
5. Elledge RM, Green s, Pugh R, Allred DC, Clark GM, Hill J, et al.<br />
Estrogen receptor (<strong>ER</strong>) and progesterone receptor (PgR), by<br />
ligand-binding assay compared with <strong>ER</strong>, PgR and ps2, by immuno-<br />
histochemistry in predicting response to tamoxifen in metastatic<br />
breast cancer: a southwest oncology Group study. Int J Cancer.<br />
2000;89:111-7.<br />
6. Allred DC, Harvey JM, berardo M, Clark GM. Prognostic and predictive<br />
factors in breast cancer by immunohistochemical analysis. Mod Pathol.<br />
1998;11:155-68.<br />
7. McGuire wl, Chamness GC, Fuqua sA. Estrogen receptor variants<br />
in clinical breast cancer. Mol Endocrinol. 1991;5:1571-7.<br />
8. Harvey JM, Clark GM, osborne CK, Allred DC. Estrogen receptor status<br />
by immunohistochemistry is superior to the ligand-binding assay for<br />
predicting response to adjuvant endocrine therapy in breast cancer.<br />
J Clin oncol. 1999;17:1474-81.<br />
9. Mohsin sK, weiss H, Havighurst t, Clark GM, berardo M, Roanh lD,<br />
et al. Progesterone receptor by immunohistochemistry and clinical<br />
outcome in breast cancer: a validation study. Modern Pathol.<br />
2004;17:1545-54.<br />
10. Phillips t, Murray G, wakamiya K, Askaa J, Huang D, welcher R, Pii K,<br />
Allred DC. Development of standard estrogen and progesterone<br />
receptor immunohistochemical assays for selection of patients for<br />
antihormonal therapy. Appl Immunohistochem Mol Morphol.<br />
2007;15:325-331.<br />
<strong>ER</strong>/<strong>PR</strong> pharmDx <strong>Interpretation</strong> <strong>Manual</strong><br />
REF<strong>ER</strong>EnCEs<br />
23
Change language